What Erecta Treats: Main Uses and Benefits

The role of Erecta (Sildenafil) is to provide symptomatic management across specific therapeutic areas. The medication is generally applicable within conditions characterized by periods of heightened symptoms, such as those involving physical discomfort or systemic imbalance.

It is commonly used in clinical scenarios where short-term symptomatic assistance is needed to manage sudden or intensifying symptom clusters. The therapeutic uses include managing symptoms related to physical discomfort and supporting relief from symptoms that interfere with daily functioning.

Supporting Stability and Comfort

This medicine is applied across conditions presenting with episodic or fluctuating manifestations, particularly where symptoms create noticeable physiological strain. It provides support that helps to ease the overall symptom burden during difficult episodes.

“This approach to symptom relief may assist with supporting functional stability during times of heightened discomfort.”

When symptoms intensify and supportive relief is needed, Erecta is relevant in clinical scenarios where the patient experiences heightened distress or discomfort. It offers symptomatic support that may help patients cope more steadily with difficult episodes and supports general well-being.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult men (aged ge 18 years) for the primary indication.
• Older adults (ge 65 years) are eligible, although reduced initial dosing may be considered due to potential changes in drug clearance.

Populations for whom use is contraindicated:

• Patients using organic nitrates in any form or the guanylate cyclase stimulator riociguat.
• Patients with a recent history of stroke or myocardial infarction.
• Individuals with severe hepatic impairment or resting hypotension (blood pressure < 90/50 mmHg).
• Men for whom sexual activity is inadvisable due to severe cardiovascular status.
• Patients with a history of vision loss from Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).

Age-related eligibility rules:

• Use is not indicated for women (including during pregnancy or lactation).
• Use is not indicated for the pediatric population (individuals below 18 years of age) for this indication.

Eligibility-related restrictions:

• Use requires caution in patients with anatomical deformation of the penis or conditions predisposing them to priapism (e.g., sickle cell anemia).
• Patients with severe renal impairment should consider a lower starting dose due to reduced drug clearance.

Interactions with other medicines and products

Erecta (Sildenafil) has officially documented interaction patterns primarily concerning its metabolic pathway and pharmacodynamic effects, as detailed in regulatory labeling.

Formal Regulatory Restrictions

Co-administration with organic nitrates or nitric oxide donors (e.g., Nitroglycerin) and Guanylate Cyclase (GC) stimulators (e.g., Riociguat) is strictly prohibited due to the risk of severe blood pressure reduction. Co-administration with other PDE5 inhibitors is generally avoided.

Pharmacokinetic and Pharmacodynamic Interactions

Sildenafil is primarily cleared from the body via the CYP3A4 enzyme system. Strong CYP3A4 inhibitors (such as Ritonavir and Ketoconazole) officially cause a significant increase in Sildenafil plasma exposure.

• Timing Rule: A mandatory maximum single dose of 25 mg in a 48-hour period applies when co-administered with Ritonavir.

Alpha-blockers are documented to cause a pharmacodynamic interaction leading to additive blood pressure lowering, with the highest risk of symptomatic hypotension noted within four hours post-dosing.

Interactions with Food and Products

Alcohol (ethanol) may potentiate the vasodilatory and blood pressure lowering effects of the medicine. Consuming a high-fat meal may officially delay the onset of activity. Grapefruit juice may cause a modest rise in plasma levels.

The primary mechanism of Erecta's active ingredient, Sildenafil, is the selective competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5), found predominantly in vascular smooth muscle. This enzyme normally hydrolyzes the intracellular messenger cyclic guanosine monophosphate (cGMP). By blocking PDE5, the drug sustains and elevates the cGMP concentration within these cells. The sustained cGMP concentration potentiates the effects of the natural physiological mediator, Nitric Oxide (NO), which initiates the signaling cascade. This potentiation drives the activation of Protein Kinase G (PKG), leading to the relaxation of vascular smooth muscle cells and subsequent vasodilation, which results in increased local blood perfusion. Crucially, the mechanism is functionally dependent upon the pre-existing release of endogenous NO; Sildenafil acts to potentiate the native signal, defining a constraint on its operation in physiological states characterized by impaired NO synthesis.

How to Use Erecta (Sildenafil) Official Administration Guidelines

Sildenafil administration follows two distinct usage patterns: intermittent (as-needed) use and continuous (scheduled) use. The medicine is authorized for the oral route via film-coated tablets across both protocols, and in certain clinical settings, the oral suspension or intravenous (IV) injection may also be used.

Usage Patterns and Administration

For intermittent use, the typical starting oral dose is 50 mg. This dose may be adjusted based on response, ranging from a reduced dose of 25 mg up to a maximum of 100 mg. This regimen dictates a strict limit of once per day. The dose may be taken orally with or without food. For specific patient populations, such as older adults or those with severe renal or hepatic impairment, a lower 25 mg starting dose should be considered.

For continuous use, such as in long-term maintenance protocols, the standard oral dose is 20 mg, taken three times a day (TID). Each dose must be spaced approximately 4 to 8 hours apart. The dose may be escalated up to 80 mg TID depending on tolerability. If using the oral suspension, the product must be shaken well for 10 seconds before administration. The IV route is reserved strictly for temporary use when oral dosing is not feasible. If a dose is missed in the continuous schedule, it should be taken as soon as possible, but compensation via a double dose is prohibited.

Research Evidence / Overview of Studies for Erecta (Sildenafil)

Evidence for Use in Erectile Dysfunction (ED)

The research for Sildenafil in Erectile Dysfunction was evaluated primarily using short-term, randomized, double-blind, placebo-controlled clinical trials (RCTs). These RCTs are applied in studies examining patient-reported experiences related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies included adult men (≥ 18 years) diagnosed with ED, and research explored specific subgroups where ED was present with conditions like diabetes mellitus and spinal cord injury. The primary outcomes used in research explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort. Specifically, studies monitored changes measured using the International Index for Erectile Function (IIEF) questionnaire, and also recorded observations regarding the ability of participants to achieve and sustain an erection sufficient for sexual intercourse.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

For Pulmonary Arterial Hypertension (PAH), the evidence was evaluated in primary research derived from randomized, double-blind, placebo-controlled clinical trials. Studies monitored both adult patients with symptomatic PAH and distinct cohorts of pediatric patients (aged 1 to 17 years). Primary endpoints examined metrics related to functional exercise capacity, measured by the 6-minute walk distance, and the observed rates of a composite outcome related to clinical worsening (such as hospitalization).

While studies monitored measurements related to adult exercise capacity over the short term, a trial conducted in the pediatric PAH population noted an observed pattern of increased mortality associated with chronic, high-dose administration. This finding was included in the regulatory assessment.

Key Evidence Gaps and Areas of Uncertainty

The research base for Sildenafil encompasses multiple clinical trials. However, a limitation is that follow-up durations were often limited across the core trials. There is limited information for long-term outcomes, and the sustained effects over multiple years are not fully established. Furthermore, the results apply only to the populations studied. Data for certain groups remain insufficient, and for the pediatric PAH population, the observed pattern of increased mortality represents a key area of uncertainty and caution.

Key Studies & References

1. International Index of Erectile Function (IIEF): Development and evaluation of an abridged, 5-item version
2. Sildenafil citrate therapy for pulmonary arterial hypertension (SUPER trial)

Common questions about Erecta (FAQ)

Q: I heard Erecta can cause headaches; is that a frequent side effect?

A: According to the official product information, headache is classified as a Very Common side effect of Erecta. This classification describes an effect that is often observed in the study populations, occurring in more than 1 in 10 individuals.

Q: Does using Erecta require a specific type of medical test beforehand?

A: Regulatory documents advise that a medical history and physical examination should be performed before the medicine is started. Official documents emphasize that the patient's cardiovascular status must be considered, which necessitates a medical history and physical examination.

Q: Can people with liver issues take Erecta?

A: Official guidance states that use is contraindicated in individuals with severe hepatic (liver) impairment for the ED indication. For patients with less severe hepatic impairment, official documents indicate that a lower starting dose may be appropriate.

Q: Can people with kidney problems use Erecta?

A: For individuals with severe renal (kidney) impairment, official regulatory texts indicate that a lower starting dose may be appropriate for the ED indication. However, for those with mild to moderate kidney impairment, no specific dose adjustment is generally required based on regulatory labeling.

Q: Is there a difference in effectiveness if Erecta is taken on an empty stomach?

A: Official product information notes that taking the medication with a high-fat meal may slow down the body's absorption rate. This can result in a delay in the time it takes for the drug to reach its maximum concentration in the blood.

Q: Is Erecta used for any condition besides its primary purpose?

A: Erecta (Sildenafil) is officially indicated for the treatment of Erectile Dysfunction (ED) and is also authorized for Pulmonary Arterial Hypertension (PAH) under a different brand name. The official regulatory documents do not list any other formally approved indications for the medicine.

Q: Is it true that Erecta is available without a prescription in some countries?

A: Regulatory bodies in certain regions, such as the UK, have allowed a specific version of the medication to be available in a pharmacy setting for adult men without a doctor's prescription. This availability is subject to an assessment by a pharmacist.

Q: How long does it usually take for Erecta to start working?

A: When taken on an empty stomach, the maximum amount of the drug in the body is generally reached between 30 and 120 minutes after taking the tablet, with a median time of 60 minutes. This range describes the time required for the drug to reach its maximum measured concentration in the body.

Q: Does taking Erecta affect future response to the medication?

A: Official regulatory documents for the ED indication do not mention the development of tolerance, which is a reduced response to the drug over time. It is noted that the evidence base for the drug relies primarily on short-term clinical trials.

Q: What is the difference between Erecta and generic versions of the drug?

A: Both the brand name Erecta and its generic versions contain the same active ingredient, Sildenafil. The main differences lie in the inactive ingredients (excipients) used in the tablet's final formulation and the specific regulatory identity of the brand name itself.

Q: Are there certain foods or drinks that should be avoided when taking Erecta?

A: Official labeling advises that consumption of a high-fat meal may delay the onset of activity of the medicine. Regulatory texts also mention that grapefruit juice may cause a small increase in the levels of the drug in the body.

Q: What should someone do if they miss taking their dose of Erecta?

A: For the continuous-use regimen (such as for PAH), if a dose is missed, regulatory guidance states that it may be taken as soon as it is remembered. However, taking a double or extra dose is strictly prohibited. The intermittent-use regimen does not have a formal missed dose procedure, as it is taken only as needed.

Q: Are there any age restrictions for using Erecta?

A: According to official documents, the use for the ED indication is not indicated for individuals under 18 years of age. For the PAH indication, the use is not recommended for children between the ages of 1 and 17 years due to an observed pattern of increased mortality associated with chronic, high-dose administration.

Q: Do studies support the long-term effectiveness of Erecta?

A: Regulatory texts confirm that the research base for Erecta primarily consists of short-term randomized clinical trials. It is stated that there is limited information available for long-term outcomes and sustained effects over multiple years.

Q: Are there any common herbs or supplements that interact with Erecta?

A: Regulatory documents identify that the drug is primarily processed by the body's CYP3A4 enzyme system. The official information warns that certain herbs or supplements that inhibit this enzyme system may lead to an increase in the drug's concentration in the bloodstream.

Q: Is it normal to feel a warming sensation after taking Erecta?

A: Official product information classifies flushing (a feeling of warmth or redness) as a Very Common side effect of Erecta. This means that a warming sensation is observed in more than 1 out of every 10 individuals who use the medicine.

Q: Why do some patients report not seeing an effect right away with Erecta?

A: The time it takes for the drug to begin working is linked to its absorption rate, which is typically median 60 minutes when taken without food. Official product information notes that the absorption rate is delayed by a high-fat meal, which may explain why some individuals do not feel an immediate effect.

Q: Is there any research on Erecta's effectiveness in people with diabetes?

A: Regulatory clinical study summaries confirm that researchers have explored specific subgroups with conditions such as diabetes mellitus in relation to the drug's main indication.

Q: Are there different forms or strengths of Erecta available?

A: Erecta is officially available as film-coated tablets in strengths including 25 mg, 50 mg, and 100 mg. For the PAH indication, the medicine is also available in different forms, including an oral suspension and an intravenous (IV) injection.

Q: Are there any specific lifestyle factors that can influence how well Erecta works?

A: Official labeling notes that the consumption of alcohol may potentiate the vasodilatory effects of the medicine. This may contribute to the vasodilatory and blood pressure lowering effects of the medicine.

Q: What precautions are listed for patients who drive or operate machinery while using Erecta?

A: Official documents advise patients to be aware of their individual reaction to the medication before driving or operating machinery. This is because adverse reactions such as dizziness and visual disturbances have been reported.

Q: Is there a maximum number of times Erecta can be used safely per week?

A: According to the official regulatory documents, the maximum recommended dosing frequency for the intermittent (as-needed) regimen is once per day.

How to Store and Dispose of Erecta

Erecta (sildenafil citrate) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The medication must be kept in its original container and protected from excess heat and moisture; therefore, storage in a bathroom is not advised.

Child Safety and Disposal

It is mandatory to store Erecta out of the sight and reach of children and pets.

Disposal of unused or expired tablets must comply with local regulations. The regulatory guidance explicitly states that the medicine should not be thrown away via wastewater or household trash. Check with a pharmacist or a local drug take-back program for proper disposal methods.